This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.
Muscimol
Surface here is educational only; do not use without medical supervision. Our editorial verdict is SKIP-FOR-NOW — current cost / risk / redundancy puts it below the line.
Our depth — beyond the mirror
Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.
▸ Editor's verdict SKIP-FOR-NOW HIGH
Recreational dissociative profile with no cognitive use case; theanine + magnesium + tryptophan/glycine cleaner for sleep/anxiety; gummy market is a vendor lottery with documented adulteration, hospitalizations, and deaths (Diamond Shruumz 2024).
▸ Decision matrix by user profile Per-archetype
| Archetype | Verdict | Rationale |
|---|---|---|
★20-30, brain-priority, high cognitive workload (the user) | SKIP-FOR-NOW | Recreational dissociative with hours of impairment, no cognitive upside. Already has theanine 200mg, magnesium glycinate + threonate, and L-tryptophan (post-V5) covering anxiolysis and sleep with vastly cleaner profiles. Adding GABA-A direct agonism at age 20with developing neural plasticity is downside-only. |
30-50, executive maintenance | SKIP | No cognitive case; same cleaner alternatives apply. |
50+, mild cognitive decline | SKIP | GABA-A agonism in older adults raises fall risk and worsens cognition acutely; especially poor fit. |
Anxiety-prone | SKIP | Ashwagandha, theanine, magnesium, propranolol PRN, low-dose buspirone, or properly prescribed benzo PRN all dominate. Muscimol's dissociation profile is wrong for daily anxiolysis. |
High athletic load, tested status | SKIP | Not WADA-banned but the next-day residual sedation kills training quality. Vomiting risk during/after training is real. |
Sleep-disordered | SKIP | Trazodone, magnesium glycinate, glycine, tryptophan, apigenin, even doxepin 3-6mg all clean alternatives. Muscimol-induced sleep is dissociative and grogginess-prone, not restorative. |
Recovery-focused (post-injury, post-illness) | SKIP | No anabolic or anti-inflammatory case; ataxia + nausea + impairment counterproductive to rehab. |
Strength/anabolic-focused | SKIP | No anabolic action; sedation + appetite disruption work against goals. |
- ★20-30, brain-priority, high cognitive workload (the user)SKIP-FOR-NOW
Recreational dissociative with hours of impairment, no cognitive upside. Already has theanine 200mg, magnesium glycinate + threonate, and L-tryptophan (post-V5) covering anxiolysis and sleep with vastly cleaner profiles. Adding GABA-A direct agonism at age 20with developing neural plasticity is downside-only.
- 30-50, executive maintenanceSKIP
No cognitive case; same cleaner alternatives apply.
- 50+, mild cognitive declineSKIP
GABA-A agonism in older adults raises fall risk and worsens cognition acutely; especially poor fit.
- Anxiety-proneSKIP
Ashwagandha, theanine, magnesium, propranolol PRN, low-dose buspirone, or properly prescribed benzo PRN all dominate. Muscimol's dissociation profile is wrong for daily anxiolysis.
- High athletic load, tested statusSKIP
Not WADA-banned but the next-day residual sedation kills training quality. Vomiting risk during/after training is real.
- Sleep-disorderedSKIP
Trazodone, magnesium glycinate, glycine, tryptophan, apigenin, even doxepin 3-6mg all clean alternatives. Muscimol-induced sleep is dissociative and grogginess-prone, not restorative.
- Recovery-focused (post-injury, post-illness)SKIP
No anabolic or anti-inflammatory case; ataxia + nausea + impairment counterproductive to rehab.
- Strength/anabolic-focusedSKIP
No anabolic action; sedation + appetite disruption work against goals.
▸ Subjective experience (deep)
Onset: 30 min - 2 hr (highly variable with food, body weight, prep method). Peak: 1-3 hr. Duration: 4-8 hr active; some effects persist up to 24 hr (residual sedation, dream-like states).
Low dose (5-7 mg muscimol): Mild relaxation, body warmth, slight dissociation, mild anxiolysis. Often described as "GABAergic" but qualitatively heavier and weirder than alcohol or benzos.
Standard psychoactive (8-15 mg): Sedation, ataxia, slurred speech, vivid dream-like states with eyes closed, dissociation from body and time, nausea, perceptual distortion. Not classically psychedelic — no visuals like psilocybin/LSD. Often profound sleep with intense dreams.
Higher (>15 mg or unpredictable gummy doses): Delirium, confusion, severe ataxia, vomiting, autonomic dysregulation (sweating, salivation from accompanying muscarine in raw mushroom), occasional seizures. Hours of being non-functional.
Common across all doses:
- Nausea / vomiting (very common, especially with raw or under-decarboxylated material)
- Loss of motor coordination
- Time distortion
- Drowsiness lasting into next day
- Memory gaps at higher doses
Variability is enormous because (a) ibotenic-to-muscimol ratio depends on preparation, (b) individual mushrooms vary 10-fold in alkaloid content, (c) commercial gummies have shown wildly inconsistent dosing and frequent adulteration with non-listed substances (synthetic cannabinoids, kratom alkaloids, NBOMe analogs in some Diamond Shruumz tests).
▸ Tolerance + cycling deep dive
- Tolerance buildup: Moderate cross-tolerance with other GABA-A ligands; rapid tolerance to subjective effects with daily use anecdotally
- Recommended cycle: N/A — not recommended at all
- Reset protocol: N/A
▸ Stacking deep dive
Synergistic with
None recommended. Theoretically additive with anything GABAergic or sedating, which is the problem, not the feature.
Avoid stacking with
- Alcohol: Additive CNS depression; multiple deaths in case reports involve co-use
- Benzodiazepines, Z-drugs: Synergistic respiratory depression
- phenibut: GABA-A direct agonism + GABA-B agonism = compounded sedation, dependence on phenibut side worsens
- baclofen: Same — GABA-A + GABA-B layered depression
- gaba-supplement: No real interaction (oral GABA barely crosses BBB) but redundant intent
- Opioids, barbiturates, ketamine: Compounded CNS depression, respiratory depression
Neutral / safe co-administration
N/A — not using.
▸ Drug interactions deep dive
Unstudied formally. Theoretical CYP interactions minimal — muscimol is mostly excreted unchanged or via simple conjugation. Real interaction risk is pharmacodynamic: anything CNS-depressant compounds the sedation/respiratory depression risk.
No specific contraceptive interactions documented.
▸ Pharmacogenomics
No characterized polymorphisms drive muscimol response in published literature. δ-GABA-A subunit variants (GABRD) plausibly modulate sensitivity but no actionable data.
▸ Sourcing deep dive
| Path | Vendor | Cost | Reliability | Notes |
|---|---|---|---|---|
| Gas station / smoke shop gummies | Various (MoonWlkr, Wunder, Hamilton's, Psyched Wellness, etc.) | $20-50/pack | LOW | FDA warning letters issued 2024-2025; CDC found Schedule I adulterants in some "nootropic" Amanita gummies (Charlottesville 2023-24 cluster) |
| Whole dried mushroom (online ethnobotanical) | iAmShaman, others | $20-60/oz | MEDIUM | Alkaloid content varies 10-fold between mushrooms; user-driven decarboxylation required |
| Pure muscimol (research chemical) | Sigma-Aldrich, Cayman Chemical | ~$200-400/100mg | HIGH (purity) | Research-use-only labeling; not for human consumption |
| Tinctures / extracts | Psyched Wellness "Calm" etc. | $40-80/bottle | MEDIUM-LOW | Better dosing consistency than gummies but still in FDA crosshairs |
FDA position (Dec 2024 letter to industry): Amanita muscaria, its extracts, muscimol, ibotenic acid, and muscarine are unapproved food additives. Food containing them is adulterated under the FFDCA. Enforcement actions continue 2025+.
No legitimate medical sourcing path in US.
▸ Biomarkers to track (deep)
N/A — not using.
▸ Controversies / open debates Live debate
- "It's natural" framing. Used heavily by gummy vendors. Irrelevant — death cap (Amanita phalloides) is also natural. Mechanism, dose, and quality matter; phylogeny doesn't.
- Mechanism vs. clinical reality. Muscimol's direct GABA-A orthosteric agonism is a genuinely interesting and rare profile in available compounds — most "GABAergic" options are PAMs (benzos, Z-drugs) or indirect. The mechanism alone has theoretical appeal (different from benzo tolerance/dependence pattern). But the actual subjective profile is worse, not better, than benzos for daily use — more dissociation, more delirium, less clean anxiolysis. Mechanism-novelty doesn't redeem profile.
- Microdosing claims vs. zero clinical evidence. Vendors and a handful of retrospective case reports promote sub-threshold Amanita microdosing for anxiety/sleep. No RCTs. The plural of anecdote isn't data, and the vendor incentive structure is obvious.
- Russian/Siberian traditional use vs. modern context. Real ethnobotanical history (Sámi, Koryak, Itelmen). But traditional use was ceremonial/shamanic with cultural infrastructure for managing the experience, not daily wellness supplementation. Importing the substance without the context misuses both.
- Western vs. Eastern European pharmacology research. Eastern European literature (Polish, Russian) has more case-report and traditional-use depth on Amanita; Western literature focuses on toxicology and receptor pharmacology. Neither side has produced clinical efficacy evidence for any therapeutic claim.
▸ Verdict change log
- 2026-05-05 — Initial verdict: SKIP-FOR-NOW (HIGH confidence). Recreational dissociative profile, no cognitive use case, FDA enforcement environment hot, gummy market is adulteration-risk lottery, the user's existing GABAergic stack (theanine + magnesium + tryptophan) covers the legitimate sleep/anxiety territory more cleanly. Not worth depth-researching further.
▸ Open questions / gaps Open
- What would change verdict? Honestly, nothing realistic in the next 5 years. Would require: (1) FDA-approved pure muscimol product with dose accuracy, (2) RCT data showing meaningful efficacy on a specific indication, (3) safety data showing it cleanly outperforms theanine/magnesium/tryptophan/PRN benzo for that indication. None of those are likely. Even Psyched Wellness's clinical work (early-stage) targets sleep — a domain the user already has covered.
- Microdose research: A real RCT (n>100, controlled, validated outcomes) on sub-threshold Amanita extract for anxiety or sleep would be informative. Not aware of any in flight that would publish before 2028+.
- Standalone pure-muscimol pharma. If a pharma company developed a controlled-dose muscimol product (low-dose, possibly transdermal or sublingual) with reliable PK, that would be a different evaluation. Not currently in the pipeline.
References
Johnston GAR. Muscimol as an Ionotropic GABA Receptor Agonist (2014)
mechanistic review of muscimol's GABA-A pharmacology
View StudyExtrasynaptic δ-GABAA receptors are high-affinity muscimol receptors (PMC)
δ-subunit selectivity and tonic inhibition mechanism
View StudyEmerging Risks of Amanita Muscaria: Case Reports (PMC, 2024-2025)
recent case-report literature on consumer harm
View StudyFDA Letter to Industry: Amanita Muscaria (Dec 2024)
official position that muscimol/ibotenic acid/muscarine are unapproved food additives; food containing them is adulterated
View SourceFDA Scientific Memorandum: Amanita Muscaria (9/9/2024)
toxicology and adverse event review supporting enforcement position
View SourceFDA Warning Letter: Blue Forest Farms LLC (09/11/2025)
recent enforcement action citing delirium, seizures, coma, respiratory depression, death
View SourceCDC: Diamond Shruumz outbreak investigation
180 illnesses, 73 hospitalizations, 3 potentially associated deaths (Oct 2024 update); muscimol detected in subset of products
View SourceCDC MMWR: Schedule I Substances in Nootropic Gummies — Charlottesville 2023-2024
adulteration documentation in Amanita gummy market
View SourceNPR: FDA targets mushroom edibles following illnesses and suspected deaths (Dec 2024)
context on enforcement and outbreak
View SourceAmerican Journal of Preventive Medicine: Public Health Response to Unregulated Sales of Amanita muscaria
00163-6/fulltext) — UCSD researchers on 114% search increase 2022-2023, market growth concerns
View SourceChange in Ibotenic Acid and Muscimol Contents during Drying, Storing or Cooking (J-Stage)
decarboxylation kinetics relevant to preparation safety
View SourcePsyched Wellness Amanita Muscaria Sleep Study
only commercial entity running formal sleep work; preliminary
View SourceHow was your experience with this compound?
Anonymous · one vote per session · results below at 5+ votes.
See something off?
Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.